default author photo

Bo Lan

Tianjin Medical University - National Clinical Research Center for Cancer

Tianjin, 300060

China

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)

SCHOLARLY PAPERS

3

DOWNLOADS

76

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

The Different Sequences of Cdk4/6 Inhibitor and Mtor Inhibitor in Hr+/Her2- Advanced Breast Cancer: A Multicenter Real-World Study

Number of pages: 19 Posted: 22 Jul 2024
Jiangxi Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Chinese Academy of Medical Sciences - Department of Medical Oncology, Beijing University, Government of the People's Republic of China - Chinese PLA General Hospital and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)
Downloads 31 (1,318,317)

Abstract:

Loading...

therapeutic sequence, CDK4/6 inhibitor, everolimus, survival outcome

2.

Dynamic Hematological Indicators Predict the Efficacy of Cdk4/6 Inhibitors in Hr-Positive, Her2-Negative Metastatic Breast Cancer: An Exploratory Analysis of the Bright-2 Trial

Number of pages: 21 Posted: 06 Aug 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Chinese Academy of Medical Sciences - Department of Medical Oncology, Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), affiliation not provided to SSRN, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Geneplus Beijing Institute, Geneplus Beijing Institute, Geneplus-Beijing Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 25 (1,411,822)

Abstract:

Loading...

Metastatic Breast Cancer, HR-positive, CDK4/6 inhibitor, prognostic factor, hematological indicator

3.

Safety and Efficacy Study of Oral Metronomic Capecitabine Combined with Pyrotinib in Her2-Positive Metastatic Breast Cancer: A Phase Ii Trial

Number of pages: 10 Posted: 22 Jun 2023
Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of VIP Medical Services, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer and Chinese Academy of Sciences (CAS)
Downloads 20 (1,448,301)

Abstract:

Loading...

Phase II study, metastatic breast cancer, HER2-positive, pyrotinib, capecitabine, metronomic chemotherapy